research use only

Emavusertib (CA-4948) IRAK inhibitor

Name: Emavusertib (CA-4948)
Brand: Selleck Chemicals
SKU: S9779
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S9779

Emavusertib (CA-4948) is a potent and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) with anti-tumor activity.

Emavusertib (CA-4948) IRAK inhibitor Chemical Structure

Quality Control

Batch: S977901 DMSO]49 mg/mL]false]Ethanol]2 mg/mL]false]Water]Insoluble]false Purity: 99.88%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.88

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Other IRAK Inhibitors	Zimlovisertib (PF-06650833) IRAK4-IN-1 JH-X-119-01 HS-243 IRAK-1-4 Inhibitor I KT-474 (SAR444656) Zabedosertib KT-413 IRAK inhibitor 6 IRAK-4 protein kinase inhibitor 2

Solubility

In vitro
Batch:

DMSO : 49 mg/mL (99.69 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (2.54mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	491.50	Formula	C₂₄H₂₅N₇O₅	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1801344-14-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=C(N=C4N=C(OC4=C3)N5CCOCC5)N6CCC(O)C6

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	IRAK4 FLT3
In vitro	Emavusertib (CA-4948) is over 500-fold more selective for IRAK-4 compared to IRAK-1. This compound reduces TNF-α, IL-1β, IL-6 and IL-8 release from TLR-Stimulated THP-1 Cells with an IC50 <250 nM. It has antiproliferative activity due to inhibition of receptor-type tyrosine-protein kinase FLT3.
In vivo	Emavusertib (CA-4948) has anti-tumour activity in animal models including tumours containing MyD88 gene mutations.
References	[1] https://pubmed.ncbi.nlm.nih.gov/32255710/ [2] https://ashpublications.org/blood/article/132/Supplement%201/4168/275778/Preclinical-Activity-of-IRAK4-Kinase-Inhibitor-CA [3] https://pubmed.ncbi.nlm.nih.gov/33335659/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-04-03)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07107750	RECRUITING	Metastatic Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma	Washington University School of Medicine	2026-03-27	PHASE1
NCT05564390	RECRUITING	Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy; Acute Myeloid Leukemia, Myelodysplasia-Related; Myelodysplastic Syndrome	National Cancer Institute (NCI)	2024-06-18	PHASE2
NCT05187182	RECRUITING	Gastric Cancer; Esophageal Cancer; Stomach Cancer; Esophagus Cancer; Gastroesophageal Junction Cancer	Washington University School of Medicine	2023-06-02	PHASE1
NCT07463820	NOT_YET_RECRUITING	Myelodysplastic Syndrome	National Cancer Institute (NCI)	2026-06-19	PHASE2
NCT07271667	RECRUITING	Chronic Lymphocytic Leukemia; B-cell Malignancies	Curis, Inc.	2026-04-23	PHASE2
NCT06439836	RECRUITING	Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma	National Cancer Institute (NCI)	2025-05-05	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):